World's Best Scientists 2026 revealed!
Adrian Newman-Tancredi

Adrian Newman-Tancredi

D-Index & Metrics

Neuroscience

D-Index
72
Citations
15092
World Ranking
2348
National Ranking
1112

Adrian Newman-Tancredi publication distribution in Neuroscience in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Neuroscience in 2026. The highlighted bar marks where Adrian Newman-Tancredi sits on this spectrum.

38–47 publications: 18 scientists 48–57 publications: 79 scientists 58–67 publications: 193 scientists 68–77 publications: 323 scientists 78–87 publications: 406 scientists 88–97 publications: 452 scientists 98–107 publications: 539 scientists 108–117 publications: 505 scientists 118–127 publications: 522 scientists 128–137 publications: 469 scientists 138–147 publications: 456 scientists 148–157 publications: 459 scientists 158–167 publications: 397 scientists 168–177 publications: 383 scientists 178–187 publications: 350 scientists 188–197 publications: 302 scientists 198–207 publications: 306 scientists 208–217 publications: 262 scientists 218–227 publications: 242 scientists 228–237 publications: 220 scientists 238–247 publications: 203 scientists 248–257 publications: 174 scientists 258–267 publications: 176 scientists 268–277 publications: 175 scientists 278–287 publications: 125 scientists 288–297 publications: 116 scientists 298–307 publications: 127 scientists 308–317 publications: 128 scientists 318–327 publications: 99 scientists 328–337 publications: 89 scientists 338–347 publications: 78 scientists 348–357 publications: 96 scientists 358–367 publications: 66 scientists 368–377 publications: 59 scientists 378–387 publications: 65 scientists 388–397 publications: 54 scientists 398–407 publications: 48 scientists 408–417 publications: 49 scientists 418–427 publications: 34 scientists 428–437 publications: 31 scientists 438–447 publications: 30 scientists 448–457 publications: 31 scientists 458–467 publications: 36 scientists 468–477 publications: 40 scientists 478–487 publications: 35 scientists 488–497 publications: 30 scientists 498–507 publications: 23 scientists 508–517 publications: 26 scientists 518–527 publications: 20 scientists 528–537 publications: 23 scientists 538–547 publications: 20 scientists 548–557 publications: 20 scientists 558–567 publications: 17 scientists 568–577 publications: 14 scientists 578–587 publications: 20 scientists 588–597 publications: 20 scientists 598–607 publications: 19 scientists 608–617 publications: 18 scientists 618–627 publications: 17 scientists 628–637 publications: 11 scientists 638–647 publications: 11 scientists 648–657 publications: 11 scientists 658–667 publications: 8 scientists 668–677 publications: 7 scientists 678–687 publications: 11 scientists 688–697 publications: 10 scientists 698–707 publications: 4 scientists 708–717 publications: 6 scientists 718–727 publications: 5 scientists 728–737 publications: 5 scientists 738–747 publications: 9 scientists 748–757 publications: 9 scientists 758–767 publications: 3 scientists 768–777 publications: 7 scientists 778–787 publications: 7 scientists 788–797 publications: 6 scientists 798–807 publications: 2 scientists 808–817 publications: 2 scientists 818–827 publications: 7 scientists 828–837 publications: 0 scientists 838–847 publications: 9 scientists 848–857 publications: 3 scientists 858–867 publications: 1 scientists 868–877 publications: 3 scientists 878–886 publications: 6 scientists 887+ publications: 100 scientists
38 publications 887+

This scientist: 276 publications — 79th percentile

79% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 887 publications or more.

Adrian Newman-Tancredi D-index placement in Neuroscience in 2026

The chart shows the D-index (discipline H-index) distribution of Neuroscience scientists ranked by Research.com in 2026. The highlighted bar marks where Adrian Newman-Tancredi sits on this spectrum.

30–31 D-Index: 42 scientists 32–33 D-Index: 172 scientists 34–35 D-Index: 296 scientists 36–37 D-Index: 435 scientists 38–39 D-Index: 459 scientists 40–41 D-Index: 456 scientists 42–43 D-Index: 467 scientists 44–45 D-Index: 478 scientists 46–47 D-Index: 512 scientists 48–49 D-Index: 435 scientists 50–51 D-Index: 425 scientists 52–53 D-Index: 418 scientists 54–55 D-Index: 392 scientists 56–57 D-Index: 357 scientists 58–59 D-Index: 334 scientists 60–61 D-Index: 328 scientists 62–63 D-Index: 260 scientists 64–65 D-Index: 278 scientists 66–67 D-Index: 239 scientists 68–69 D-Index: 250 scientists 70–71 D-Index: 210 scientists 72–73 D-Index: 200 scientists 74–75 D-Index: 189 scientists 76–77 D-Index: 170 scientists 78–79 D-Index: 146 scientists 80–81 D-Index: 113 scientists 82–83 D-Index: 126 scientists 84–85 D-Index: 100 scientists 86–87 D-Index: 84 scientists 88–89 D-Index: 99 scientists 90–91 D-Index: 84 scientists 92–93 D-Index: 85 scientists 94–95 D-Index: 72 scientists 96–97 D-Index: 76 scientists 98–99 D-Index: 45 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 43 scientists 104–105 D-Index: 32 scientists 106–107 D-Index: 45 scientists 108–109 D-Index: 50 scientists 110–111 D-Index: 32 scientists 112–113 D-Index: 39 scientists 114–115 D-Index: 32 scientists 116–117 D-Index: 29 scientists 118–119 D-Index: 27 scientists 120–121 D-Index: 19 scientists 122–123 D-Index: 23 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 16 scientists 128–129 D-Index: 24 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 21 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 14 scientists 138–139 D-Index: 15 scientists 140–141 D-Index: 10 scientists 142–143 D-Index: 10 scientists 144–145 D-Index: 13 scientists 146–147 D-Index: 9 scientists 148–149 D-Index: 8 scientists 150–151 D-Index: 6 scientists 152–153 D-Index: 6 scientists 154–155 D-Index: 7 scientists 156–157 D-Index: 7 scientists 158–159 D-Index: 10 scientists 160–161 D-Index: 4 scientists 162 D-Index: 8 scientists 163+ D-Index: 100 scientists
30 D-Index 163+

This scientist: 72 D-Index — 77th percentile

77% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 163 D-Index or more.

Overview

Adrian Newman-Tancredi is affiliated with Neurolixis in the United States and has an extensive publication record primarily in the fields of neuroscience, biochemistry, genetics and molecular biology, and medicine. Their research spans several subfields including cellular and molecular neuroscience, molecular biology, pharmacology, neurology, and cognitive neuroscience.

The main research topics covered by Newman-Tancredi focus on neurotransmitter receptor influence on behavior, neuroscience and neuropharmacology research, receptor mechanisms and signaling, treatment of major depression, tryptophan and brain disorders, Parkinson's disease mechanisms and treatments, as well as neurological disorders and treatments.

Frequent publication venues for their research include Neuropharmacology, bioRxiv (Cold Spring Harbor Laboratory), Journal of Medicinal Chemistry, Translational Psychiatry, and Behavioural Brain Research.

Newman-Tancredi has collaborated extensively with several co-authors, notably:

  • Ronan Depoortère
  • Mark A. Varney
  • Luc Zimmer
  • Marcin Kołaczkowski
  • Mariusz Papp

Significant recent publications by Adrian Newman-Tancredi include:

  • "Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders" (2021), Pharmacology & Therapeutics
  • "International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function" (2020), Pharmacological Reviews
  • "Perspectives for therapy of treatment-resistant depression" (2021), British Journal of Pharmacology
  • "The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets" (2020), Neuropharmacology
  • "The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques" (2020), Parkinsonism & Related Disorders

Best Publications

  • The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways

    Mark J. Millan;Alain Gobert;Françoise Lejeune;Anne Dekeyne

  • Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes

    Mark J. Millan;Lisa Maiofiss;Didier Cussac;Valérie Audinot

  • Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat

    Alain Gobert;Jean‐Michel Rivet;Françoise Lejeune;Adrian Newman‐Tancredi

  • Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release

    A Gobert;J.-M Rivet;V Audinot;A Newman-Tancredi

  • Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a []GTPγS binding study

    Adrian Newman-Tancredi;Samantha Gavaudan;Caroline Conte;Christine Chaput

  • Agonist and antagonist actions of yohimbine as compared to fluparoxan at alpha(2)-adrenergic receptors (AR)s, serotonin (5-HT)(1A), 5-HT(1B), 5-HT(1D) and dopamine D(2) and D(3) receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states.

    Mark J. Millan;Adrian Newman‐Tancredi;Valérie Audinot;Didier Cussac

  • 5-HT(1A) [corrected] receptors in mood and anxiety: recent insights into autoreceptor versus heteroreceptor function.

    Alvaro L. Garcia-Garcia;Adrian Newman-Tancredi;E. David Leonardo

  • Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor.

    Adrian Newman-Tancredi;Didier Cussac;Valérie Audinot;Jean-Paul Nicolas

  • International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function

    Nicholas M. Barnes;Gerard P. Ahern;Carine Becamel;Joël Bockaert

  • Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.

    M. J. Millan;A. Gobert;J. M. Rivet;A. Adhumeau-Auclair

  • Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes

    Adrian Newman-Tancredi;Didier Cussac;Yann Quentric;Manuelle Touzard

  • S33005, a Novel Ligand at Both Serotonin and Norepinephrine Transporters: I. Receptor Binding, Electrophysiological, and Neurochemical Profile in Comparison with Venlafaxine, Reboxetine, Citalopram, and Clomipramine

    Mark J. Millan;Alain Gobert;Françoise Lejeune;Adrian Newman-Tancredi

  • Comparative pharmacology of antipsychotics possessing combined dopamine D2 and serotonin 5-HT1A receptor properties.

    Adrian Newman-Tancredi;Mark S. Kleven

  • Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5-HT2A sites for PCP-induced locomotion in the rat.

    M. J. Millan;M. Brocco;A. Gobert;F. Joly

  • A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194.

    Valérie Audinot;Adrian Newman-Tancredi;Alain Gobert;Jean-Michel Rivet

  • Chronic restraint stress induces mechanical and cold allodynia, and enhances inflammatory pain in rat: Relevance to human stress-associated painful pathologies

    L. Bardin;N. Malfetes;A. Newman-Tancredi;R. Depoortère

  • Actions of alpha2 adrenoceptor ligands at alpha2A and 5-HT1A receptors: the antagonist, atipamezole, and the agonist, dexmedetomidine, are highly selective for alpha2A adrenoceptors.

    A Newman-Tancredi;J P Nicolas;V Audinot;S Gavaudan

  • S33084, a novel, potent, selective, and competitive antagonist at dopamine D(3)-receptors: I. Receptorial, electrophysiological and neurochemical profile compared with GR218,231 and L741,626.

    Mark J. Millan;Alain Gobert;Adrian Newman-Tancredi;Françoise Lejeune

  • Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.

    M J Millan;J L Peglion;J Vian;J M Rivet

  • Clozapine is a partial agonist at cloned, human serotonin 5-HT1A receptors.

    A. Newman-Tancredi;C. Chaput;L. Verriele;M.J. Millan

  • Contrasting Contribution of 5-Hydroxytryptamine 1A Receptor Activation to Neurochemical Profile of Novel Antipsychotics: Frontocortical Dopamine and Hippocampal Serotonin Release in Rat Brain

    Marie-Bernadette Assié;Véronique Ravailhe;Valérie Faucillon;Adrian Newman-Tancredi

  • Levomilnacipran (F2695), a norepinephrine-preferring SNRI: profile in vitro and in models of depression and anxiety.

    A.L. Auclair;J.C. Martel;M.B. Assié;L. Bardin

Frequent Co-Authors

Mark J. Millan
Mark J. Millan University of Glasgow
Alain P. Gobert
Alain P. Gobert Vanderbilt University Medical Center
Jean A. Boutin
Jean A. Boutin Institut de Recherches Internationales Servier
Thierry Billard
Thierry Billard Lyon College
Nicolas Costes
Nicolas Costes Grenoble Alpes University
Michael Spedding
Michael Spedding DuPont (United States)
Wouter Koek
Wouter Koek The University of Texas Health Science Center at San Antonio
Pau Celada
Pau Celada Spanish National Research Council
Philip G. Strange
Philip G. Strange University of Reading
Francesc Artigas
Francesc Artigas Spanish National Research Council

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a degree in neuroscience can open doors to a variety of connected fields. If you are exploring alternative or supplementary career paths, several online programs offer flexible and affordable options that complement neuroscience studies.

For those interested in clinical or counseling roles, accredited marriage and family therapy online programs accredited provide the skills needed to work with individuals, couples, and families. Psychology remains a top choice, and you may consider a cheapest online master's degree in psychology or a online psychology degree cheap to deepen your understanding of human behavior while managing costs.

Additionally, graduates with a background in neuroscience often pursue social work, leveraging their expertise to support mental health initiatives. If this interests you, explore the easiest msw online program to gain the qualifications needed to practice as a social worker.

These online pathways offer both flexibility and affordability, making it easier to build a career that aligns with your neuroscience background and professional interests.

Best Scientists Citing Adrian Newman-Tancredi

Trending Scientists

Recently Published Articles